Bcal Diagnostics Limited (ASX:BDX)

11.8¢

right-arrow Created with Sketch. -0.008 (-6%)
MCAP $25.86M
Last trade 15.32pm 18/01/2022 20mins delayed

Latest Announcements

11/01/2022 Price SensitivePSBDXBcal Diagnostics Limited
29/12/2021BDXBcal Diagnostics Limited
13/12/2021BDXBcal Diagnostics Limited
13/12/2021BDXBcal Diagnostics Limited
23/11/2021BDXBcal Diagnostics Limited
22/11/2021BDXBcal Diagnostics Limited
22/11/2021BDXBcal Diagnostics Limited
251
MCap
08/11/2021BDXBcal Diagnostics Limited

Company Overview

BCAL Diagnostics Limited (BCAL) is an Australia-based screening and diagnostic company. The Company is developing a blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, accurate and available to all women regardless of age, race and geographic location. It has developed a non-invasive blood test for the detection of breast cancer. The Company is developing an in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vehicles (EVs) from a patient's plasma or blood sample to diagnose the presence of cancer cells in a patient’s body. BCAL has partnered with integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across jurisdictions.

BDX in the news

Breast cancer screening and diagnostic company BCAL Diagnostics (BDX) names Dr John…

Search Previous Announcements